<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:30:51Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8444839" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8444839</identifier>
        <datestamp>2021-09-17</datestamp>
        <setSpec>pheblackwell</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="bjh17644" xml:lang="en" article-type="letter">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Br J Haematol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Br J Haematol</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1365-2141</journal-id>
              <journal-id journal-id-type="publisher-id">BJH</journal-id>
              <journal-title-group>
                <journal-title>British Journal of Haematology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0007-1048</issn>
              <issn pub-type="epub">1365-2141</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8444839</article-id>
              <article-id pub-id-type="pmcid">PMC8444839</article-id>
              <article-id pub-id-type="pmc-uid">8444839</article-id>
              <article-id pub-id-type="pmid">34132395</article-id>
              <article-id pub-id-type="doi">10.1111/bjh.17644</article-id>
              <article-id pub-id-type="publisher-id">BJH17644</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Correspondence</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Covid‐19</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms</article-title>
              </title-group>
              <contrib-group>
                <contrib id="bjh17644-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Chowdhury</surname>
                    <given-names>Onima</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8150-4088</contrib-id>
                  <xref rid="bjh17644-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <address>
                    <email>onima.chowdhury@ndcls.ox.ac.uk</email>
                  </address>
                </contrib>
                <contrib id="bjh17644-cr-0002" contrib-type="author">
                  <name>
                    <surname>Bruguier</surname>
                    <given-names>Hannah</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0003" contrib-type="author">
                  <name>
                    <surname>Mallett</surname>
                    <given-names>Garry</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0004" contrib-type="author">
                  <name>
                    <surname>Sousos</surname>
                    <given-names>Nikolaos</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9100-2954</contrib-id>
                  <xref rid="bjh17644-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0005" contrib-type="author">
                  <name>
                    <surname>Crozier</surname>
                    <given-names>Kirsty</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0006" contrib-type="author">
                  <name>
                    <surname>Allman</surname>
                    <given-names>Caroline</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0007" contrib-type="author">
                  <name>
                    <surname>Eyre</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0008" contrib-type="author">
                  <name>
                    <surname>Lumley</surname>
                    <given-names>Sheila</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0009" contrib-type="author">
                  <name>
                    <surname>Strickland</surname>
                    <given-names>Marie</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0010" contrib-type="author">
                  <name>
                    <surname>Karali</surname>
                    <given-names>Christina S.</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0011" contrib-type="author">
                  <name>
                    <surname>Murphy</surname>
                    <given-names>Lauren</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0012" contrib-type="author">
                  <name>
                    <surname>Sternberg</surname>
                    <given-names>Alex</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0013" contrib-type="author">
                  <name>
                    <surname>Jeffery</surname>
                    <given-names>Katie</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0014" contrib-type="author">
                  <name>
                    <surname>Mead</surname>
                    <given-names>Adam J.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8522-1002</contrib-id>
                  <xref rid="bjh17644-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0015" contrib-type="author">
                  <name>
                    <surname>Peniket</surname>
                    <given-names>Andy</given-names>
                  </name>
                  <xref rid="bjh17644-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="bjh17644-cr-0016" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Psaila</surname>
                    <given-names>Bethan</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8198-9663</contrib-id>
                  <xref rid="bjh17644-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="bjh17644-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <address>
                    <email>bethan.psaila@ndcls.ox.ac.uk</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="bjh17644-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">MRC Molecular Haematology Unit</named-content>
                <institution>MRC Weatherall Institute of Molecular Medicine</institution>
                <institution>University of Oxford</institution>
                <city>Oxford</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="bjh17644-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>National Institute of Health Research Oxford Biomedical Research Centre</institution>
                <city>Oxford</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="bjh17644-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Haematology</named-content>
                <institution>Churchill Hospital</institution>
                <institution>Oxford University Hospitals’ NHS Foundation Trust</institution>
                <city>Oxford</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="bjh17644-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Nuffield Department of Population Health</named-content>
                <institution>Big Data Institute</institution>
                <institution>University of Oxford</institution>
                <city>Oxford</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="bjh17644-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Department of Microbiology</named-content>
                <institution>Oxford University Hospitals’ NHS Foundation Trust</institution>
                <city>Oxford</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="bjh17644-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Nuffield Department of Medicine</named-content>
                <institution>University of Oxford</institution>
                <city>Oxford</city>
                <country country="GB">UK</country>
              </aff>
              <pub-date pub-type="epub">
                <day>24</day>
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>24</day>
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>194</volume>
              <issue seq="120">6</issue>
              <issue-id pub-id-type="doi">10.1111/bjh.v194.6</issue-id>
              <fpage>1010</fpage>
              <lpage>1015</lpage>
              <permissions>
                <!--Copyright &#x000a9; 2021 John Wiley & Sons Ltd-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley &amp; Sons Ltd.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:BJH-194-1010.pdf"/>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>MRC CARP award</funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>Cancer Research UK Advanced Clinician Scientist Fellowship</funding-source>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>BRC Senior Fellowship</funding-source>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>CRUK DPhil studentship</funding-source>
                </award-group>
                <award-group id="funding-0005">
                  <funding-source>Emerson Collective</funding-source>
                </award-group>
                <award-group id="funding-0006">
                  <funding-source>ASH EHA Translational Research Training in Hematology Program</funding-source>
                </award-group>
                <award-group id="funding-0007">
                  <funding-source>National Institute of Health Research (NIHR)</funding-source>
                </award-group>
                <award-group id="funding-0008">
                  <funding-source>Oxford Biomedical Research Centre (BRC)</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="1"/>
                <page-count count="6"/>
                <word-count count="3661"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>September 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.7 mode:remove_FC converted:16.09.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body id="bjh17644-body-0001">
            <p>The COVID‐19 pandemic has had a severe impact on people with blood cancers. Patients with blood cancer are at an increased risk of poor outcomes after COVID‐19 infection, with more severe infections and a higher case fatality rate,<xref rid="bjh17644-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="bjh17644-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="bjh17644-bib-0003" ref-type="bibr"><sup>3</sup></xref> which may reflect immunocompromise due to their underlying disease and/or immunosuppressive treatments. As a result, regulatory approval and the subsequent rapid roll out of COVID‐19 vaccines has been extremely well received by the blood cancer community. However, the registry trials of the currently approved vaccines largely excluded patients with blood cancers. Immune responses in this diverse group therefore require urgent study to ensure that these vulnerable patients are adequately protected from severe COVID‐19 infection.</p>
            <p>A recent study demonstrated substantially reduced seroconversion rates post‐COVID‐19 vaccination in oncology patients, when compared to healthcare worker (HCW) controls, following a single dose of the Pfizer‐BioNTech BNT162b2 vaccine. Response rates were &gt;90% in HCWs but &lt;40% in patients with solid cancers, and strikingly low (&lt;15%) in the 56 patients studied with haematological malignancy.<xref rid="bjh17644-bib-0004" ref-type="bibr"><sup>4</sup></xref> Impaired immunity and reduced seroconversion are unsurprising in a heavily treated patient group, those with aggressive disease, marked cytopenias, and those with B‐cell neoplasms. This study only included three patients with myelodysplastic syndrome (MDS)/myeloproliferative neoplasms (MPNs) and myelofibrosis (MF) and none with chronic myeloid leukaemia (CML). Responses in patients with chronic myeloid neoplasms, many of whom are minimally treated and have normal or only mildly deranged blood counts, might be expected to be less severely impaired, and therefore warrant specific study.</p>
            <p>We therefore sought to gather real‐world data by measuring anti‐SARS‐CoV‐2 IgG spike (S) antibody levels, more than two weeks following a single dose of either BNT162b2 or the AstraZeneca‐Oxford ChAdOx1 nCoV‐19 (AZD1222) vaccines in patients with CML, essential thrombocythemia (ET), polycythaemia vera (PV), MF and MDS attending the Churchill Hospital Myeloid Clinic, Oxford University Hospital, UK. Patients with clinical or laboratory evidence of prior COVID‐19 infection were excluded from the study. As part of routine clinical blood sampling, quantitative anti‐S antibody titres were measured using the EU compliant (CE‐marked) Abbott SARS‐CoV‐2 IgG II Quant Assay (Maidenhead, UK) (positive threshold: ≥ 50 AU/ml) and anti‐nucleocapsid (N) antibodies (indicative of past infection) were measured using the Abbott SARS‐CoV‐2 IgG assay. Leucocyte immunophenotyping (T/B/NK cell subsets) and serology to other previous immunizations (tetanus and pneumococcus) were also measured. Deidentified data on HCWs was used as a comparative cohort, obtained from the Infections in Oxfordshire Research Database (Research Ethics Committee, Health Research Authority and Confidentiality Advisory Group approvals: 19/SC/0403, 19/CAG/0144).</p>
            <p>Between 1st January and 30 April 2021, samples were collected on 60 myeloid cancer patients with no prior clinical or laboratory evidence of prior COVID‐19 infection (CML, <italic toggle="yes">n</italic> = 12; ET, <italic toggle="yes">n</italic> = 17; MF/pre‐fibrotic MF, <italic toggle="yes">n</italic> = 7; PV, <italic toggle="yes">n</italic> = 11 and MDS, <italic toggle="yes">n</italic> = 13; Table <xref rid="bjh17644-tbl-0001" ref-type="table"> I</xref>). One patient with ET (ID 19) was subsequently found to have anti‐N antibodies indicative of past COVID‐19 infection, and was therefore excluded from further analysis. The median age of the cohort was 62 [interquartile range (IQR) = 52–73], with a similar number being male (<italic toggle="yes">n</italic> = 27) and female (<italic toggle="yes">n</italic> = 32). The majority were of white ethnicity, reflecting the local patient population. Seventy‐one percent (42/59 patients) were on active therapies, including hydroxycarbamide (<italic toggle="yes">n</italic> = 11), pegylated interferon (<italic toggle="yes">n</italic> = 8), ruxolitinib (<italic toggle="yes">n</italic> = 4), hydroxycarbamide and ruxolitinib (<italic toggle="yes">n</italic> = 1), BET inhibitor (<italic toggle="yes">n</italic> = 1) and tyrosine kinase inhibitors (TKI; imatinib <italic toggle="yes">n</italic> = 6; dasatinib <italic toggle="yes">n</italic> = 2; nilotinib <italic toggle="yes">n</italic> = 2; bosutinib <italic toggle="yes">n</italic> = 2). MDS patients were receiving azacitidine (<italic toggle="yes">n</italic> = 3), erythropoietin (<italic toggle="yes">n</italic> = 3) or an IDH1 inhibitor (<italic toggle="yes">n</italic> = 1). Twenty‐nine percent of patients (17/59) were not receiving any cytoreductive treatments or TKI. The median interval between vaccination and anti‐S antibody measurement was 34 days (IQR 28–56).</p>
            <table-wrap position="float" id="bjh17644-tbl-0001" content-type="Table">
              <label>Table I</label>
              <caption>
                <p>Demographics and clinical characteristics of patient cohort with serological response.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <col style="border-right:solid 1px #000000" span="1"/>
                <col style="border-right:solid 1px #000000" span="1"/>
                <col style="border-right:solid 1px #000000" span="1"/>
                <col style="border-right:solid 1px #000000" span="1"/>
                <col style="border-right:solid 1px #000000" span="1"/>
                <col style="border-right:solid 1px #000000" span="1"/>
                <col style="border-right:solid 1px #000000" span="1"/>
                <col style="border-right:solid 1px #000000" span="1"/>
                <col style="border-right:solid 1px #000000" span="1"/>
                <thead valign="top">
                  <tr style="border-bottom:solid 1px #000000">
                    <th align="left" valign="top" rowspan="1" colspan="1">ID</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Age</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Sex</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">AZ or Pfizer</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">No. days between vaccine and anti‐S testing</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Anti‐S titre (AU/ml)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Anti‐S positive or negative</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Diagnosis</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Current cytoreductive treatment/TKI</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">1</td>
                    <td align="char" char="." rowspan="1" colspan="1">72</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">28</td>
                    <td align="left" rowspan="1" colspan="1">16·8</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Imatinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">2</td>
                    <td align="char" char="." rowspan="1" colspan="1">62</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">28</td>
                    <td align="left" rowspan="1" colspan="1">54·2</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Imatinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">3</td>
                    <td align="char" char="." rowspan="1" colspan="1">40</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">46</td>
                    <td align="left" rowspan="1" colspan="1">111·1</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Imatinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">4</td>
                    <td align="char" char="." rowspan="1" colspan="1">53</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">28</td>
                    <td align="left" rowspan="1" colspan="1">257·8</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Imatinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">5</td>
                    <td align="char" char="." rowspan="1" colspan="1">52</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">28</td>
                    <td align="left" rowspan="1" colspan="1">90·2</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Imatinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">6</td>
                    <td align="char" char="." rowspan="1" colspan="1">47</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">56</td>
                    <td align="left" rowspan="1" colspan="1">559·5</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Imatinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">7</td>
                    <td align="char" char="." rowspan="1" colspan="1">60</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">31</td>
                    <td align="left" rowspan="1" colspan="1">104·9</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Nilotinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">8</td>
                    <td align="char" char="." rowspan="1" colspan="1">31</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">67</td>
                    <td align="left" rowspan="1" colspan="1">375·2</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Nilotinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">9</td>
                    <td align="char" char="." rowspan="1" colspan="1">67</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">28</td>
                    <td align="left" rowspan="1" colspan="1">31·1</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Bosutinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">10</td>
                    <td align="char" char="." rowspan="1" colspan="1">35</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">34</td>
                    <td align="left" rowspan="1" colspan="1">354·6</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Bosutinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">11</td>
                    <td align="char" char="." rowspan="1" colspan="1">47</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">31</td>
                    <td align="left" rowspan="1" colspan="1">49·3</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Dasatinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">12</td>
                    <td align="char" char="." rowspan="1" colspan="1">52</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">31</td>
                    <td align="left" rowspan="1" colspan="1">3428</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">CML</td>
                    <td align="left" rowspan="1" colspan="1">Dasatinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">13</td>
                    <td align="char" char="." rowspan="1" colspan="1">77</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">26</td>
                    <td align="left" rowspan="1" colspan="1">195·1</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Anagrelide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">14</td>
                    <td align="char" char="." rowspan="1" colspan="1">79</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">68</td>
                    <td align="left" rowspan="1" colspan="1">19·9</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">15</td>
                    <td align="char" char="." rowspan="1" colspan="1">76</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">47</td>
                    <td align="left" rowspan="1" colspan="1">41·8</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">16</td>
                    <td align="char" char="." rowspan="1" colspan="1">54</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">38</td>
                    <td align="left" rowspan="1" colspan="1">2·4</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">17</td>
                    <td align="char" char="." rowspan="1" colspan="1">69</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">55</td>
                    <td align="left" rowspan="1" colspan="1">14·10</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">18</td>
                    <td align="char" char="." rowspan="1" colspan="1">72</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">28</td>
                    <td align="left" rowspan="1" colspan="1">961·2</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">
                      <italic toggle="yes">19</italic>
                    </td>
                    <td align="char" char="." rowspan="1" colspan="1">
                      <italic toggle="yes">49</italic>
                    </td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic toggle="yes">F</italic>
                    </td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic toggle="yes">Pfizer</italic>
                    </td>
                    <td align="char" char="." rowspan="1" colspan="1">
                      <italic toggle="yes">8</italic>
                    </td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic toggle="yes">19 538·2</italic>
                    </td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic toggle="yes">Pos</italic>
                    </td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic toggle="yes">ET</italic>
                    </td>
                    <td align="left" rowspan="1" colspan="1">
                      <italic toggle="yes">Hydroxycarbamide</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">20</td>
                    <td align="char" char="." rowspan="1" colspan="1">57</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">68</td>
                    <td align="left" rowspan="1" colspan="1">393·7</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">21</td>
                    <td align="char" char="." rowspan="1" colspan="1">67</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">24</td>
                    <td align="left" rowspan="1" colspan="1">4·8</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Interferon</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">22</td>
                    <td align="char" char="." rowspan="1" colspan="1">52</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">35</td>
                    <td align="left" rowspan="1" colspan="1">828·7</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Interferon</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">23</td>
                    <td align="char" char="." rowspan="1" colspan="1">48</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">55</td>
                    <td align="left" rowspan="1" colspan="1">328·1</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Interferon</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">24</td>
                    <td align="char" char="." rowspan="1" colspan="1">47</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">34</td>
                    <td align="left" rowspan="1" colspan="1">134·3</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Interferon</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">25</td>
                    <td align="char" char="." rowspan="1" colspan="1">48</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">83</td>
                    <td align="left" rowspan="1" colspan="1">68·2</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Interferon</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">26</td>
                    <td align="char" char="." rowspan="1" colspan="1">41</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">7</td>
                    <td align="left" rowspan="1" colspan="1">1944·7</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">None</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">27</td>
                    <td align="char" char="." rowspan="1" colspan="1">53</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">41</td>
                    <td align="left" rowspan="1" colspan="1">111·60</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">None</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">28</td>
                    <td align="char" char="." rowspan="1" colspan="1">49</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">82</td>
                    <td align="left" rowspan="1" colspan="1">110·8</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">None</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">29</td>
                    <td align="char" char="." rowspan="1" colspan="1">54</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">21</td>
                    <td align="left" rowspan="1" colspan="1">12·7</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">ET</td>
                    <td align="left" rowspan="1" colspan="1">Ruxolitinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">30</td>
                    <td align="char" char="." rowspan="1" colspan="1">55</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">32</td>
                    <td align="left" rowspan="1" colspan="1">5·9</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">PV</td>
                    <td align="left" rowspan="1" colspan="1">Hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">31</td>
                    <td align="char" char="." rowspan="1" colspan="1">71</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">60</td>
                    <td align="left" rowspan="1" colspan="1">41·7</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">PV</td>
                    <td align="left" rowspan="1" colspan="1">Hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">32</td>
                    <td align="char" char="." rowspan="1" colspan="1">58</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">65</td>
                    <td align="left" rowspan="1" colspan="1">37·5</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">PV</td>
                    <td align="left" rowspan="1" colspan="1">Hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">33</td>
                    <td align="char" char="." rowspan="1" colspan="1">56</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">41</td>
                    <td align="left" rowspan="1" colspan="1">242·8</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">PV</td>
                    <td align="left" rowspan="1" colspan="1">Hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">34</td>
                    <td align="char" char="." rowspan="1" colspan="1">70</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">27</td>
                    <td align="left" rowspan="1" colspan="1">1758·9</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">PV</td>
                    <td align="left" rowspan="1" colspan="1">Hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">35</td>
                    <td align="char" char="." rowspan="1" colspan="1">51</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">30</td>
                    <td align="left" rowspan="1" colspan="1">793·6</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">PV</td>
                    <td align="left" rowspan="1" colspan="1">Interferon</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">36</td>
                    <td align="char" char="." rowspan="1" colspan="1">54</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">31</td>
                    <td align="left" rowspan="1" colspan="1">209·5</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">PV</td>
                    <td align="left" rowspan="1" colspan="1">Interferon</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">37</td>
                    <td align="char" char="." rowspan="1" colspan="1">71</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">28</td>
                    <td align="left" rowspan="1" colspan="1">6·7</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">PV</td>
                    <td align="left" rowspan="1" colspan="1">Ruxolitinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">38</td>
                    <td align="char" char="." rowspan="1" colspan="1">65</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">47</td>
                    <td align="left" rowspan="1" colspan="1">4·9</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">PV</td>
                    <td align="left" rowspan="1" colspan="1">Ruxolitinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">39</td>
                    <td align="char" char="." rowspan="1" colspan="1">85</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">76</td>
                    <td align="left" rowspan="1" colspan="1">27·7</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">PV</td>
                    <td align="left" rowspan="1" colspan="1">Venesection</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">40</td>
                    <td align="char" char="." rowspan="1" colspan="1">81</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">73</td>
                    <td align="left" rowspan="1" colspan="1">2374·6</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">PV</td>
                    <td align="left" rowspan="1" colspan="1">Venesection</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">41</td>
                    <td align="char" char="." rowspan="1" colspan="1">62</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">50</td>
                    <td align="left" rowspan="1" colspan="1">152·5</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">MF</td>
                    <td align="left" rowspan="1" colspan="1">BET inhibitor</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">42</td>
                    <td align="char" char="." rowspan="1" colspan="1">79</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">48</td>
                    <td align="left" rowspan="1" colspan="1">308·9</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">MF</td>
                    <td align="left" rowspan="1" colspan="1">Darbopoietin</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">43</td>
                    <td align="char" char="." rowspan="1" colspan="1">51</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">47</td>
                    <td align="left" rowspan="1" colspan="1">159·2</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">MF</td>
                    <td align="left" rowspan="1" colspan="1">None</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">44</td>
                    <td align="char" char="." rowspan="1" colspan="1">69</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">31</td>
                    <td align="left" rowspan="1" colspan="1">22·9</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">MF</td>
                    <td align="left" rowspan="1" colspan="1">None</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">45</td>
                    <td align="char" char="." rowspan="1" colspan="1">70</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">65</td>
                    <td align="left" rowspan="1" colspan="1">3·1</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">MF</td>
                    <td align="left" rowspan="1" colspan="1">Ruxolitinib + hydroxycarbamide</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">46</td>
                    <td align="char" char="." rowspan="1" colspan="1">74</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">23</td>
                    <td align="left" rowspan="1" colspan="1">46·8</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">MF</td>
                    <td align="left" rowspan="1" colspan="1">Ruxolitinib</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">47</td>
                    <td align="char" char="." rowspan="1" colspan="1">48</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">32</td>
                    <td align="left" rowspan="1" colspan="1">1406</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">Pre‐fibrotic MF</td>
                    <td align="left" rowspan="1" colspan="1">Interferon</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">48</td>
                    <td align="char" char="." rowspan="1" colspan="1">74</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">74</td>
                    <td align="left" rowspan="1" colspan="1">8·1</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">Azacitidine</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">49</td>
                    <td align="char" char="." rowspan="1" colspan="1">69</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">69</td>
                    <td align="left" rowspan="1" colspan="1">5·7</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">Azacitidine</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">50</td>
                    <td align="char" char="." rowspan="1" colspan="1">74</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">28</td>
                    <td align="left" rowspan="1" colspan="1">51·6</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">Azacitidine</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">51</td>
                    <td align="char" char="." rowspan="1" colspan="1">57</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">14</td>
                    <td align="left" rowspan="1" colspan="1">75·3</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">Darbopoietin</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">52</td>
                    <td align="char" char="." rowspan="1" colspan="1">86</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">60</td>
                    <td align="left" rowspan="1" colspan="1">55·3</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">Darbopoietin</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">53</td>
                    <td align="char" char="." rowspan="1" colspan="1">76</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">21</td>
                    <td align="left" rowspan="1" colspan="1">1·7</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">None</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">54</td>
                    <td align="char" char="." rowspan="1" colspan="1">58</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">AZ</td>
                    <td align="char" char="." rowspan="1" colspan="1">66</td>
                    <td align="left" rowspan="1" colspan="1">4255</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">None</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">55</td>
                    <td align="char" char="." rowspan="1" colspan="1">88</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">20</td>
                    <td align="left" rowspan="1" colspan="1">47·7</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">None</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">56</td>
                    <td align="char" char="." rowspan="1" colspan="1">76</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">45</td>
                    <td align="left" rowspan="1" colspan="1">4·8</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">Transfusions</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">57</td>
                    <td align="char" char="." rowspan="1" colspan="1">83</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">15</td>
                    <td align="left" rowspan="1" colspan="1">7·6</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">Transfusions</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">58</td>
                    <td align="char" char="." rowspan="1" colspan="1">82</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">56</td>
                    <td align="left" rowspan="1" colspan="1">1345·3</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">Transfusions</td>
                  </tr>
                  <tr>
                    <td align="char" char="." rowspan="1" colspan="1">59</td>
                    <td align="char" char="." rowspan="1" colspan="1">72</td>
                    <td align="left" rowspan="1" colspan="1">F</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">29</td>
                    <td align="left" rowspan="1" colspan="1">159·2</td>
                    <td align="left" rowspan="1" colspan="1">Pos</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">Transfusions</td>
                  </tr>
                  <tr style="border-bottom:solid 1px #000000">
                    <td align="char" char="." rowspan="1" colspan="1">60</td>
                    <td align="char" char="." rowspan="1" colspan="1">73</td>
                    <td align="left" rowspan="1" colspan="1">M</td>
                    <td align="left" rowspan="1" colspan="1">Pfizer</td>
                    <td align="char" char="." rowspan="1" colspan="1">17</td>
                    <td align="left" rowspan="1" colspan="1">19·1</td>
                    <td align="left" rowspan="1" colspan="1">Neg</td>
                    <td align="left" rowspan="1" colspan="1">MDS</td>
                    <td align="left" rowspan="1" colspan="1">IDH1 inhibitor</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot id="bjh17644-ntgp-0001">
                <fn id="bjh17644-note-0001">
                  <p>Patient 19 (italic font) was found to have positive anti‐N antibodies indicative of past COVID‐19 infection, and was excluded from subsequent analysis. CML, chronic myeloid laukaemia; ET, essential thrombocythemia; PV, polycythaemia vera; MF, myelofibrosis; MDS, myelodysplastic syndrome; TKI, tyrosine kinase inhibitors.</p>
                </fn>
              </table-wrap-foot>
              <permissions>
                <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
              </permissions>
            </table-wrap>
            <p>Serological responses &gt;14 days after a single dose of BNT162b2 or AZD1222 vaccine in HCWs (i.e. predominately healthy adults) with no clinical or laboratory evidence of past COVID‐19 exposure have been reported at almost 100% (2706/2720 [99·5%] after BNT162b2 and 864/890 [97·1%] following AZD1222).<xref rid="bjh17644-bib-0005" ref-type="bibr"><sup>5</sup></xref> As a comparative control group for our patient cohort, we collated the serological responses from a large cohort of 232 HCWs aged &gt;60 years [median age 62 (range 60–76)]. In HCWs of a comparable age to our patient cohort, seroconversion rates were also extremely high [166/169 (98%) and 58/63 (92%) for BNT162b2 and AZD1222 respectively], &gt;14 days following the first vaccine dose (Fig <xref rid="bjh17644-fig-0001" ref-type="fig">1A,B</xref>).</p>
            <fig position="float" fig-type="Fig" id="bjh17644-fig-0001">
              <label>Fig 1</label>
              <caption>
                <p>Seroconversion of patients with chronic myeloid neoplasms compared to controls post a single COVID‐19 vaccination. (A) Percentage of patients with a chronic myeloid malignancy (<italic toggle="yes">n</italic> = 59) <italic toggle="yes">versus</italic> healthcare worker (HCW) controls (<italic toggle="yes">n</italic> = 232) of a similar age (&gt;60 years), with positive anti‐spike (anti‐S) serology and no evidence of past COVID‐19 infection [224/232 (97%) HCW vs 34/59 (58%) patients; <italic toggle="yes">P</italic> &lt; 0·0001]. (B) Median anti‐S titre (AU/ml) after a single dose of vaccine in HCWs aged &gt;60 years and in patients with a chronic myeloid malignancy {HCWs 630 [interquartile range (IQR) 284–1 328] vs. myeloid 75 (IQR 19–328); <italic toggle="yes">P</italic> &lt; 0·0001}. (C) Percentage patients with positive anti‐S serology according to disease subtype: chronic myeloid leukaemia (9/12 = 75%), essential thrombocythemia (ET 10/16 = 63%), polycythaemia vera (PV 4/11 = 46%), myelofibrosis (MF 3/6 = 50%) and myelodysplastic syndrome (MDS 6/13 = 46%). (D) Percentage patients with positive anti‐S serology according to vaccine received (AZD1222 19/31 [59%] vs. BNT162b 212/21 [55%]; <italic toggle="yes">P</italic> = 0·79). Mann–Whitney <italic toggle="yes">U</italic> and Fisher’s exact test were used for statistical comparisons of continuous and categorical variables respectively.</p>
              </caption>
              <graphic xlink:href="BJH-194-1010-g001" position="anchor" id="jats-graphic-1"/>
            </fig>
            <p>In stark contrast, seroconversion measured using the same anti‐S antibody assay &gt;14 days after a single vaccination dose in patients with chronic myeloid blood cancers was only 58%, significantly lower than in HCWs of similar age [224/232 (97%) HCW vs 34/59 (58%) patients; <italic toggle="yes">P</italic> &lt; 0·0001; Fig. <xref rid="bjh17644-fig-0001" ref-type="fig">1A</xref>]. The median anti‐S antibody titre was also significantly lower [630 (IQR 284–1328) vs 75 (IQR 19–328); <italic toggle="yes">P</italic> &lt; 0·0001; Fig <xref rid="bjh17644-fig-0001" ref-type="fig">1B</xref>].</p>
            <p>When split into disease subgroups, seroconversion was highest in patients with CML (75%; Fig. <xref rid="bjh17644-fig-0001" ref-type="fig">1C</xref>), and observed in 5/6 (83%) of CML patients receiving imatinib (Table <xref rid="bjh17644-tbl-0001" ref-type="table"> I</xref>). There was no difference in seroconversion according to which vaccine was received [22/37 (59%) and 12/22 (55%); <italic toggle="yes">P</italic> = 0·79] for AZD1222 and BNT162b2 respectively (Fig. <xref rid="bjh17644-fig-0001" ref-type="fig">1D</xref>). While robust interrogation of responses according to treatment regimens was limited by the cohort size, highest response rates (88%, or 7/8 patients) were observed in MPN patients receiving pegylated interferon, but none of the four patients receiving ruxolitinib (MF <italic toggle="yes">n</italic> = 1; ET <italic toggle="yes">n</italic> = 1; PV <italic toggle="yes">n</italic> = 2) and only 36% receiving hydroxycarbamide (4/11 patients; PV <italic toggle="yes">n</italic> = 5; ET <italic toggle="yes">n</italic> = 6) had positive anti‐S serology following the first dose of COVID‐19 vaccination (Table <xref rid="bjh17644-tbl-0001" ref-type="table"> I</xref>). Only 65% (11/17) of patients not receiving any cytoreductive therapy or TKI seroconverted.</p>
            <p>There was no difference in the median time from vaccine to anti‐S testing in the patients with positive anti‐S antibodies compared to those without [positive anti‐S: median 34·5 days (IQR 28–56); negative anti‐S median 32 days (IQR 23·5–62·5)], suggesting that the lower rate of seroconversion in the patients with myeloid neoplasms compared to the HCWs was not due to a decline in antibody levels over time.</p>
            <p>Tetanus and pneumococcal serology were available for 27 patients and demonstrated immunity in all but one patient. In addition to a complete blood count differential, detailed lymphocyte subset analysis by flow cytometry was performed in 39/59 patients, of whom 15% (6/39) were lymphopenic (lymphocyte count &lt;1·0 × 10<sup>9</sup>/l). Among the lymphopenic patients, 4/6 had a reduction in both absolute CD19 and CD3 cell counts (Table <xref rid="bjh17644-sup-0001" ref-type="supplementary-material">SI</xref>). No association was found between absolute lymphocyte count and anti‐S seroconversion [positive anti‐S: median lymphocyte count 1·74 × 10<sup>9</sup>/l (IQR 1·46–2.2); negative anti‐S median lymphocyte count 1·5 × 10<sup>9</sup>/l (IQR 1·1–1.8)].</p>
            <p>There is a clear need to protect patients with haematological disorders from COVID‐19 infection and its complications, and to design effective vaccination programmes. This analysis demonstrates that seroconversion rates in patients with chronic myeloid neoplasms are higher than those reported in more aggressive blood neoplasms or those on intensive treatments,<xref rid="bjh17644-bib-0004" ref-type="bibr"><sup>4</sup></xref> or studies in patients with B‐cell neoplasms.<xref rid="bjh17644-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="bjh17644-bib-0007" ref-type="bibr"><sup>7</sup></xref> We observed here reasonably high seroconversion rates following a single vaccine dose in patients with CML and in MPN patients receiving interferon, but humoral responses in certain MPN and MDS patients, especially those in patients receiving ruxolitinib and hydroxycarbamide, were found to be substantially impaired as compared to responses in healthy adults of a similar age group. T‐cell‐mediated immunity was not assessed, which may have slightly underestimated the functional response rates to vaccination. Nonetheless, these findings clearly demonstrate an impairment of humoral response. The mechanism for this is not yet known, but is suggestive of both disease‐ and treatment‐mediated immune dysfunction. Although our data show almost ubiquitous presence of anti‐tetanus and pneumococcus antibodies, previous studies in patients with MPNs have also suggested reduced B‐ and T‐cell‐mediated immune responses following vaccination against influenza A strains.<xref rid="bjh17644-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="bjh17644-bib-0009" ref-type="bibr"><sup>9</sup></xref>
</p>
            <p>The poor seroconversion rates in a group of patients with chronic blood cancers, including those who are not on cytoreductive treatments, those who are in complete haematological remission or major molecular response, suggest a clear need for detailed study and careful interrogation of COVID‐19 vaccination regimens in potentially vulnerable patient groups.<xref rid="bjh17644-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="bjh17644-bib-0011" ref-type="bibr"><sup>11</sup></xref> Further study with longer‐term follow‐up is required to determine responses to booster vaccine doses, and whether the observation of reduced seroconversion following first vaccine dose will be associated with higher rates of COVID‐19 infection. While it is expected that a higher proportion of patients will respond following booster vaccine doses, the suboptimal responses observed here to the first vaccine dose highlight an unexpected and potentially important immunocompromise in this patient group, which will be informative for planning our ongoing response to this evolving pandemic.</p>
            <sec id="bjh17644-sec-0003">
              <title>Funding information</title>
              <p>OC is supported by an MRC CARP award. BP is supported by a Cancer Research UK Advanced Clinician Scientist Fellowship and a BRC Senior Fellowship. NS is supported by a CRUK DPhil studentship. LM is supported by a research grant from the Emerson Collective. OC and BP have received ongoing mentorship from the ASH EHA Translational Research Training in Hematology programme. This work was supported by funding from the National Institute of Health Research (NIHR) Oxford Biomedical Research Centre (BRC).</p>
            </sec>
            <sec id="bjh17644-sec-0004">
              <title>Author contributions</title>
              <p>OC and BP designed the study, collected and interpreted data and wrote the manuscript. HB, GM, NS, KC, CA, MS, CSK and LM collected samples and data, DE, SL and KJ collected data on the HCW and contributed to overall data interpretation, AS, AJM and AP recruited patients and contributed to data interpretation and study design.</p>
            </sec>
            <sec sec-type="COI-statement" id="bjh17644-sec-0005">
              <title>Conflicts of interest</title>
              <p>None.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="bjh17644-sup-0001" position="float" content-type="local-data">
                <caption>
                  <p> </p>
                </caption>
                <media xlink:href="BJH-194-1010-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="bjh17644-sec-0002">
              <title>Acknowledgements</title>
              <p>We would like to thank the patients and clinical staff at the Churchill Hospital for supporting this study.</p>
            </ack>
            <ref-list content-type="cited-references" id="bjh17644-bibl-0001">
              <title>References</title>
              <ref id="bjh17644-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="bjh17644-cit-0001"><string-name><surname>Lee</surname><given-names>LYW</given-names></string-name>, <string-name><surname>Cazier</surname><given-names>J‐B</given-names></string-name>, <string-name><surname>Angelis</surname><given-names>V</given-names></string-name>, <string-name><surname>Arnold</surname><given-names>R</given-names></string-name>, <string-name><surname>Bisht</surname><given-names>V</given-names></string-name>, <string-name><surname>Campton</surname><given-names>NA</given-names></string-name>, et al. <article-title>COVID‐19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10241</issue>):<fpage>1919</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">32473682</pub-id></mixed-citation>
              </ref>
              <ref id="bjh17644-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="bjh17644-cit-0002"><string-name><surname>Williamson</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Walker</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Bhaskaran</surname><given-names>K</given-names></string-name>, <string-name><surname>Bacon</surname><given-names>S</given-names></string-name>, <string-name><surname>Bates</surname><given-names>C</given-names></string-name>, <string-name><surname>Morton</surname><given-names>CE</given-names></string-name>, et al. <article-title>Factors associated with COVID‐19‐related death using OpenSAFELY</article-title>. <source>Nature</source>. <year>2020</year>;<volume>584</volume>(<issue>7821</issue>):<fpage>430</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">32640463</pub-id></mixed-citation>
              </ref>
              <ref id="bjh17644-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="bjh17644-cit-0003"><string-name><surname>Salisbury</surname><given-names>RA</given-names></string-name>, <string-name><surname>Curto‐Garcia</surname><given-names>N</given-names></string-name>, <string-name><surname>O’Sullivan</surname><given-names>J</given-names></string-name>, <string-name><surname>Chen</surname><given-names>F</given-names></string-name>, <string-name><surname>Polzella</surname><given-names>P</given-names></string-name>, <string-name><surname>Godfrey</surname><given-names>AL</given-names></string-name>, et al. <article-title>Results of a national UK physician reported survey of COVID‐19 infection in patients with a myeloproliferative neoplasm</article-title>. <source>Leukemia</source>. <year>2021</year>;<fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/s41375-021-01143-2</pub-id>.<pub-id pub-id-type="pmid">32647323</pub-id></mixed-citation>
              </ref>
              <ref id="bjh17644-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="bjh17644-cit-0004"><string-name><surname>Monin‐Aldama</surname><given-names>L</given-names></string-name>, <string-name><surname>Laing</surname><given-names>AG</given-names></string-name>, <string-name><surname>Muñoz‐Ruiz</surname><given-names>M</given-names></string-name>, <string-name><surname>McKenzie</surname><given-names>DR</given-names></string-name>, <string-name>del <surname>Molino del Barrio</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Alaguthurai</surname><given-names>T</given-names></string-name>, et al. <article-title>Interim results of the safety and immune‐efficacy of 1 versus 2 doses of COVID‐19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines</article-title>. <source>medRxiv</source>. <year>2021</year>:2021.03.17.21253131. <pub-id pub-id-type="doi">10.1101/2021.03.17.21253131</pub-id>
</mixed-citation>
              </ref>
              <ref id="bjh17644-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="bjh17644-cit-0005"><string-name><surname>Eyre</surname><given-names>DW</given-names></string-name>, <string-name><surname>Lumley</surname><given-names>SF</given-names></string-name>, <string-name><surname>Wei</surname><given-names>J</given-names></string-name>, <string-name><surname>Cox</surname><given-names>S</given-names></string-name>, <string-name><surname>James</surname><given-names>T</given-names></string-name>, <string-name><surname>Justice</surname><given-names>A</given-names></string-name>, et al. <article-title>Quantitative SARS‐CoV‐2 anti‐spike responses to Pfizer‐BioNTech and Oxford‐AstraZeneca vaccines by previous infection status</article-title>. <source>medRxiv</source>. <year>2021</year>:2021.03.21.21254061.</mixed-citation>
              </ref>
              <ref id="bjh17644-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="bjh17644-cit-0006"><string-name><surname>Herishanu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Avivi</surname><given-names>I</given-names></string-name>, <string-name><surname>Aharon</surname><given-names>A</given-names></string-name>, <string-name><surname>Shefer</surname><given-names>G</given-names></string-name>, <string-name><surname>Levi</surname><given-names>S</given-names></string-name>, <string-name><surname>Bronstein</surname><given-names>Y</given-names></string-name>, et al. <article-title>Efficacy of the BNT162b2 mRNA COVID‐19 vaccine in patients with chronic lymphocytic leukemia</article-title>. <source>Blood</source>. <year>2021</year>. <pub-id pub-id-type="doi">10.1182/blood.2021011568</pub-id>
</mixed-citation>
              </ref>
              <ref id="bjh17644-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="bjh17644-cit-0007"><string-name><surname>Bird</surname><given-names>S</given-names></string-name>, <string-name><surname>Panopoulou</surname><given-names>A</given-names></string-name>, <string-name><surname>Shea</surname><given-names>RL</given-names></string-name>, <string-name><surname>Tsui</surname><given-names>M</given-names></string-name>, <string-name><surname>Saso</surname><given-names>R</given-names></string-name>, <string-name><surname>Sud</surname><given-names>A</given-names></string-name>, et al. <article-title>Response to first vaccination against SARS‐CoV‐2 in patients with multiple myeloma</article-title>. <source>Lancet Haematol</source>. <year>2021</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e389</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="pmid">33887255</pub-id></mixed-citation>
              </ref>
              <ref id="bjh17644-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="bjh17644-cit-0008"><string-name><surname>Alimam</surname><given-names>S</given-names></string-name>, <string-name><surname>Ann Timms</surname><given-names>J</given-names></string-name>, <string-name><surname>Harrison</surname><given-names>CN</given-names></string-name>, <string-name><surname>Dillon</surname><given-names>R</given-names></string-name>, <string-name><surname>Mare</surname><given-names>T</given-names></string-name>, <string-name><surname>DeLavallade</surname><given-names>H</given-names></string-name>, et al. <article-title>Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms</article-title>. <source>Br J Haematol</source>. <year>2021</year>;<volume>193</volume>(<issue>1</issue>):<fpage>150</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">33159465</pub-id></mixed-citation>
              </ref>
              <ref id="bjh17644-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="bjh17644-cit-0009"><string-name>de <surname>Lavallade</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Garland</surname><given-names>P</given-names></string-name>, <string-name><surname>Sekine</surname><given-names>T</given-names></string-name>, <string-name><surname>Hoschler</surname><given-names>K</given-names></string-name>, <string-name><surname>Marin</surname><given-names>D</given-names></string-name>, <string-name><surname>Stringaris</surname><given-names>K</given-names></string-name>, et al. <article-title>Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host</article-title>. <source>Haematologica</source>. <year>2011</year>;<volume>96</volume>(<issue>2</issue>):<fpage>307</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">20971824</pub-id></mixed-citation>
              </ref>
              <ref id="bjh17644-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="bjh17644-cit-0010"><string-name><surname>Vijenthira</surname><given-names>A</given-names></string-name>, <string-name><surname>Gong</surname><given-names>IY</given-names></string-name>, <string-name><surname>Fox</surname><given-names>TA</given-names></string-name>, <string-name><surname>Booth</surname><given-names>S</given-names></string-name>, <string-name><surname>Cook</surname><given-names>G</given-names></string-name>, <string-name><surname>Fattizzo</surname><given-names>B</given-names></string-name>, et al. <article-title>Outcomes of patients with hematologic malignancies and COVID‐19: a systematic review and meta‐analysis of 3377 patients</article-title>. <source>Blood</source>. <year>2020</year>;<volume>136</volume>(<issue>25</issue>):<fpage>2881</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="pmid">33113551</pub-id></mixed-citation>
              </ref>
              <ref id="bjh17644-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="bjh17644-cit-0011"><string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Berger</surname><given-names>NA</given-names></string-name>, <string-name><surname>Xu</surname><given-names>R</given-names></string-name>. <article-title>When hematologic malignancies meet COVID‐19 in the United States: infections, death and disparities</article-title>. <source>Blood Rev</source>. <year>2021</year>;<volume>47</volume>:<fpage>100775</fpage>.<pub-id pub-id-type="pmid">33187811</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
